VVN432
/ VivaVision, E-nitiate Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 03, 2025
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: VivaVision Biotech, Inc
New P1 trial • Otorhinolaryngology • Respiratory Diseases • Sinusitis
1 to 1
Of
1
Go to page
1